New delivery strategy may improve chemotherapy for acute myeloid leukemia

21 September 2022

CNL augments the efficacy of cytarabine/venetoclax treatment in in vivo AML models. (A–C) Bioluminescence images (A), their quantification (B) and survival of MOLM-13 Luc-YFP bearing NRG mice (C) treated for 12 days with control or CNL (30 mg/kg; intravenous; every other day), Ara-C (25 mg/kg; intraperitoneally), and venetoclax (100 mg/kg; oral gavage) both 5 days on/2 days off then 5 days on again alone or in combination. N = 5/group. B: "p